For infants with biliary atresia, undergoing standard Kasai surgery — a procedure to restore the flow of the digestive…
Articles by Steve Bryson, PhD
The most recent assessment of liver stiffness best predicts the future risk of liver disease progression among adults with…
Health Canada has conditionally approved Gilead Sciences’ seladelpar — to be marketed in the country under the brand name…
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function…
Hepatocellular carcinoma (HCC), the most common type of liver cancer, is relatively rare among people with primary sclerosing cholangitis…
A class of medicines called PPAR agonists that modulate genes involved in inflammation and scarring improve biochemical markers of liver…
E-therapeutics announced positive preclinical toxicology data on ETX-312, its therapy for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe…
Six months of treatment with lanifibranor, Inventiva’s experimental therapy, reduced abnormalities in liver sinusoidal endothelial cells (LSECs) in people…
Biliary atresia, a rare liver disease affecting infants, may be diagnosed before birth using a novel artificial intelligence (AI)…
Combining the levels of two liver damage markers, obtained from standard blood tests, can accurately discriminate infants with biliary…